Bristol Myers Squibb completes Karuna Therapeutics buyout By Investing.com Bristol Myers Squibb completes Karuna Therapeutics buyout…
Karuna Therapeutics set to merge with Bristol-Myers Squibb By Investing.com Karuna Therapeutics set to merge with Bristol-Myers Squibb…
Bristol-Myers Squibb: Großes Interesse an ADC-Playern - Tubulis holt hochkarätige Investoren an Bord - Aktienanalyse Kulmbach (www.aktiencheck.de) - Bristol-Myers Squibb-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt die Aktie von Bristol-Myers Squibb Company…
Bristol-Myers Squibb Company (BMY) Management Presents at Leerink Partners Global Biopharma Conference 2024 Conference (Transcript) …
Bristol Myers, Moderna und Roche ziehen Anti Virus-Index auf Jahreshoch Der Global Anti Virus Health Net Return Index hat in den zurückliegenden Tagen von der Mehrheit der Indexmitglieder Rückenwind erhalten.…
Societe Generale cuts Bristol-Myers Squibb to Hold By Investing.com Societe Generale cuts Bristol-Myers Squibb to Hold…
Chemotherapy Induced Peripheral Neuropathy Treatment Global Market Report 2024, Featuring Sanofi, Bristol Myers Squibb, Abbott Laboratories, Takeda Pharmaceutical and Amgen Dublin, March 08, 2024 (GLOBE NEWSWIRE) -- The "Chemotherapy Induced Peripheral Neuropathy Treatment Global Market Report 2024" has…
Follicular Lymphoma Market to Witness Upsurge in Growth by 2032, Predicts DelveInsight | Key Companies - AbbVie, Genmab, Novartis, Allogene Therapeutics, Pfizer, Genentech, Incyte Corporation, Bristol-Myers Squibb The dynamics of the follicular lymphoma market are anticipated to change in the coming years owing to the improvement in…
Bristol Myers Squibb completes RayzeBio acquisition By Investing.com Bristol Myers Squibb completes RayzeBio acquisition…
Milliardendeal: Bristol-Myers will Biopharmaunternehmen Karuna kaufen NEW YORK (dpa-AFX) - Der US-Pharmakonzern Bristol-Myers Squibb will seinen Konkurrenten Karuna Therapeutics übernehmen. Die…
Zunehmende Konkurrenz für Krebsmedikament macht Pharmakonzern BMS zu schaffen NEW YORK (dpa-AFX) - Der US-Pharmakonzern Bristol Myers Squibb (BMS) kämpft weiter mit zunehmender Konkurrenz…